Los Angeles Capital Management LLC Trims Stock Position in Catalent, Inc. (NYSE:CTLT)

Los Angeles Capital Management LLC trimmed its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 95.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,966 shares of the company’s stock after selling 89,233 shares during the period. Los Angeles Capital Management LLC’s holdings in Catalent were worth $224,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after buying an additional 365,648 shares during the last quarter. Capital World Investors lifted its stake in shares of Catalent by 6.1% during the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after purchasing an additional 1,098,474 shares during the period. Nomura Holdings Inc. boosted its holdings in shares of Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the last quarter. Cadian Capital Management LP grew its position in shares of Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after purchasing an additional 759,600 shares during the period. Finally, Ameriprise Financial Inc. grew its position in shares of Catalent by 65.9% in the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have commented on CTLT. Stephens restated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. StockNews.com began coverage on Catalent in a report on Saturday, June 22nd. They set a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $54.05.

Catalent Price Performance

Shares of NYSE CTLT opened at $56.40 on Friday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $60.20. The company has a market capitalization of $10.21 billion, a price-to-earnings ratio of -9.25, a PEG ratio of 10.69 and a beta of 1.20. The business has a 50-day moving average of $55.55 and a 200-day moving average of $53.62.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, equities analysts anticipate that Catalent, Inc. will post 0.18 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.31% of the stock is currently owned by insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.